1.72
+0.035(+2.08%)
Currency In USD
Address
3350 Riverwood Parkway SE
Atlanta, GA 30339
United States of America
Phone
678 392 3419
Website
Sector
Healthcare
Industry
Biotechnology
Employees
15
First IPO Date
December 23, 2020
| Name | Title | Pay | Year Born |
| Mark T. Iwicki | CEO & Director | 0 | 1966 |
| David John McIntyre | Chief Financial Officer | 531,333 | 1970 |
| Christopher H. Cabell | President, Head of Research & Development and Chief Medical Officer | 0 | 1969 |
| John Adams | Chief Scientific Officer | 0 | N/A |
| Chadwick J. Orevillo | Executive Vice President & Head of Development Operations | 0 | N/A |
| Jeffrey J. Kagy | Chief Human Resources Officer | 0 | N/A |
| Timothy J. Pigot | Chief Commercial & Strategy Officer | 0 | 1971 |
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.